Dual inhibitor therapy may be safer for patients with chronic lymphocytic leukemia

Can't see this email? View it online

	Hematology
	The latest hematology news from News Medical

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.

			Stanford researchers develop a portable device for rapidly detecting blood ammonia levels Seated around the dinner table, faculty affiliated with Stanford ChEM-H - one of Stanford University's interdisciplinary institutes - spoke one-by-one, pitching ideas for collaborative research.

			New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

	Study finds more effective treatment for children with sickle cell anemia A team of international researchers has learned that dose escalation of hydroxyurea treatment for children in Uganda with sickle cell anemia is more effective and has similar side effects than a lower fixed dose of the same drug.

	Takeda provides updates on its pharmacokinetic-guided prophylaxis studies at ISTH 2020, reinforcing its commitment to advancing personalized care for people with bleeding disorders Takeda Pharmaceutical Company Limited today announced that 13 abstracts are being presented from the company’s Hematology portfolio and pipeline at the International Society on Thrombosis and Haemostasis 2020 Virtual Congress.

	New nanoconjugate blocks dissemination of tumor cells in animal models of acute myeloid leukemia The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions